Impax Asset Management Group plc Purchases 221,604 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Impax Asset Management Group plc increased its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 41.3% during the 3rd quarter, Holdings Channel reports. The fund owned 758,521 shares of the company’s stock after buying an additional 221,604 shares during the quarter. Impax Asset Management Group plc’s holdings in SI-BONE were worth $10,604,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Champlain Investment Partners LLC lifted its stake in SI-BONE by 104.8% in the first quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock valued at $40,158,000 after buying an additional 1,255,610 shares in the last quarter. Bellevue Group AG lifted its stake in SI-BONE by 810.5% in the first quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock valued at $18,661,000 after buying an additional 1,014,756 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in SI-BONE by 222.5% in the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company’s stock valued at $8,674,000 after buying an additional 428,110 shares in the last quarter. American Century Companies Inc. lifted its stake in SI-BONE by 22.8% in the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock valued at $25,685,000 after buying an additional 368,637 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY lifted its stake in SI-BONE by 24.7% in the second quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock valued at $17,448,000 after buying an additional 267,100 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SIBN. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a research note on Wednesday. Morgan Stanley cut their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Finally, Truist Financial boosted their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $23.00.

Insider Buying and Selling

In related news, insider Anthony J. Recupero sold 3,305 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total transaction of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares in the company, valued at approximately $3,169,734.96. The trade was a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 7,147 shares of company stock worth $102,194. Insiders own 3.90% of the company’s stock.

SI-BONE Price Performance

Shares of SIBN opened at $12.92 on Friday. The company has a market cap of $541.86 million, a price-to-earnings ratio of -14.04 and a beta of 1.22. SI-BONE, Inc. has a 1-year low of $11.76 and a 1-year high of $21.70. The company’s fifty day simple moving average is $14.03 and its 200 day simple moving average is $14.29. The company has a current ratio of 8.25, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.